Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Analysis
Verdict: AVOID
Clinical progress in CRB-913 is offset by rapid cash burn and risk of severe equity dilution before commercialization.
Investment score: 32/100
Analysis as of
Is Corbus Pharmaceuticals Holdings Inc stock worth reviewing? AI model thesis
Corbus Pharmaceuticals offers clinical potential in obesity and oncology, but faces heavy cash burn (-$64.5M FCF TTM) and looming dilution.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Corbus Pharmaceuticals Holdings Inc opportunities and risks
What speaks for CRBP
- Phase 1b CANYON-1 data for CRB-913 showed 5% weight loss at 12 weeks without psychiatric adverse events.
What speaks against CRBP
- Extreme cash burn rate with annual operating cash flow of -$64.5M vs $28.5M in cash.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CRBP | n/a | 0.0x | n/a | 0.0% | 0.0% | -64.6% |
| ARMP | n/a | 46.4x | n/a | 68.2% | -5825.3% | -16.8% |
| SPRB | n/a | 0.0x | n/a | 0.0% | 0.0% | -28.5% |
| TNYA | n/a | 108.3x | n/a | 263.7% | -7724.0% | -49.7% |
| CRBU | n/a | 12.9x | n/a | -129.7% | -1030.4% | -74.2% |
| Peer median | n/a | 29.6x | n/a | 34.1% | -3427.9% | -39.1% |
Frequently asked questions about Corbus Pharmaceuticals Holdings Inc (CRBP)
Is CRBP stock a good investment?
The cached TradeMates AI model rates Corbus Pharmaceuticals Holdings Inc as AVOID with an investment score of 32/100. Corbus Pharmaceuticals offers clinical potential in obesity and oncology, but faces heavy cash burn (-$64.5M FCF TTM) and looming dilution. This is algorithmic model output, not personal investment advice.
Is CRBP stock a buy?
The TradeMates model verdict for CRBP is AVOID with an investment score of 32/100. Treat this as a model signal to review, not a personal buy recommendation.